Michelle Wiltse's pitch is deceptively straightforward: What if your veterinarian could see what you see at home?
That question drives CompanAIn, the Charleston-based pet wellness startup that closed a $1 million pre-seed round from unnamed investors in the animal health industry, announced on June 23, 2026. The funding, disclosed in late June, arrives just as the year-old company introduced a veterinary portal—a tool meant to stitch together clinical records with the messy, daily observations that pet owners accumulate between checkups.
It's an old problem dressed in new software. Your dog stops eating with the usual enthusiasm. Your cat's gait seems slightly off. Your horse isn't moving quite right after turnout. These small behavioral shifts rarely make it into formal medical records, yet they often signal trouble before a crisis emerges. CompanAIn is betting that artificial intelligence can bridge that gap, perhaps turning fragmented anecdotes into something clinicians can actually use.
Whether the model works—commercially, clinically—remains an open question. But the timing is instructive.
When Wellness Becomes Data
The platform itself functions as what the company calls a "living health timeline." Owners log observations—appetite changes, activity levels, anything that feels noteworthy—and the system layers those notes onto clinical data pulled from veterinary visits. The AI component scans for patterns, flagging trends that might warrant a call to the clinic.
The newly announced Veterinary Portal gives practitioners synchronized access to this longitudinal record, complete with AI-generated insights and monitoring alerts. Wiltse, who founded the company, has framed the effort as a move beyond the kind of fragmented health tracking that dominates the consumer pet tech space: fitness collars here, symptom loggers there, nothing quite connecting.
Her team includes in-house veterinary expertise—Dr. Kaori Davis, a diplomate of the American College of Veterinary Pathologists, and Dr. Kate Echeverria, board-certified in large animal internal medicine, among them. The company also assembled a veterinary advisory board late last year, a common move for startups seeking clinical credibility.
CompanAIn went live in mid-February. Three weeks later, it opened a Wellness Marketplace, turning health insights into product recommendations. Leap Years Cellular Health System for Dogs signed on as the first brand partner, according to trade publication coverage in early March. An iOS app offers tiered in-app purchases for premium features; Android support is still in development. LinkedIn lists the team size between 11 and 50 employees, though such figures are self-reported and often inflated.
Chasing a Humanization Trend
The context is hard to ignore. The American Pet Products Association pegged U.S. pet industry spending north of $150 billion recently, with services—veterinary care, grooming, boarding—claiming a growing share. Pet ownership stands at 67% of American households, and the so-called "pet humanization" trend shows no sign of slowing. Owners increasingly treat animals like family members, which translates into preventative care, functional nutrition, and a willingness to spend on marginal improvements in quality of life.
That shift has drawn capital and competition. Pluto Pets markets a similar platform. AI scribes, practice management systems, and owner-facing portals are proliferating across veterinary tech. Biotech ventures like Loyal are approaching the longevity question from the therapeutic side, targeting drugs that might extend canine lifespans. It's a crowded field, and differentiation isn't always obvious.
CompanAIn has not disclosed how it plans to deploy the pre-seed capital, beyond a vague reference to expanding its advisory board alongside the portal launch. The investors, notably, remain unnamed—a choice that's increasingly common at the earliest stages but leaves questions about strategic backing unanswered.
What Comes Next
For now, the company is in a familiar startup phase: building, iterating, hoping early traction turns into something sustainable. The veterinary portal is new enough that real-world feedback will take months to accumulate. Whether clinics adopt the tool, whether owners stick with the platform beyond initial curiosity, whether the AI actually surfaces useful patterns—those are empirical questions, not yet answered.
Wiltse's bet is that the data exists but isn't being captured. Maybe she's right. Or maybe the friction between what owners notice and what veterinarians need remains higher than software alone can solve.
Either way, CompanAIn is running the experiment. And in a market this large, even niche success can be lucrative.
